Comparative Pharmacology
Head-to-head clinical analysis: DESFLURANE versus ETHRANE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DESFLURANE versus ETHRANE.
DESFLURANE vs ETHRANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Desflurane is a volatile general anesthetic that potentiates inhibitory GABA and glycine neurotransmission and inhibits excitatory NMDA glutamate receptors, leading to neuronal hyperpolarization and reduced neuronal excitability.
Enflurane is a volatile inhalational anesthetic that potentiates GABA-A receptor activity and inhibits excitatory neurotransmission, resulting in general anesthesia.
Induction: 3-12% inhaled, titrated to effect; maintenance: 2-6% inhaled, adjusted to maintain adequate anesthetic depth with up to 1 MAC (6.0% at 37°C, 1 atm).
1-5% inspired concentration via inhalation, titrated to effect for maintenance of general anesthesia.
None Documented
None Documented
Clinical Note
moderateDesflurane + Torasemide
"The risk or severity of adverse effects can be increased when Desflurane is combined with Torasemide."
Clinical Note
moderateDesflurane + Etacrynic acid
"The risk or severity of adverse effects can be increased when Desflurane is combined with Etacrynic acid."
Clinical Note
moderateDesflurane + Furosemide
"The risk or severity of adverse effects can be increased when Desflurane is combined with Furosemide."
Clinical Note
moderateDesflurane + Bumetanide
Terminal elimination half-life is 3.5–4.5 minutes (context-sensitive half-life after prolonged anesthesia can be longer due to distribution, but true elimination is rapid due to low blood/gas partition coefficient).
Context-sensitive half-life: approximately 2-5 minutes after short procedures; prolonged after prolonged administration due to slow washout from fat stores.
Primarily eliminated via exhalation; minimal hepatic metabolism (<0.02%). Renal excretion of metabolites negligible. >99% excreted unchanged by lungs.
Primarily exhaled unchanged via lungs (>95%); less than 5% metabolized in liver to fluoride ion and other metabolites, with renal excretion of metabolites.
Category C
Category C
General Anesthetic
General Anesthetic
"The risk or severity of adverse effects can be increased when Desflurane is combined with Bumetanide."